Brain Performance and Nutrition Research centre
Newcastle upon Tyne, Tyne and Wear, NE1 8ST, United Kingdom
NCT Number: NCT03475823
Two doses (475 mg and 950 mg) of Sideritis Scardica (SS or 'mountain tea') are investigated for cognitive, mood, blood pressure and cerebral blood flow effects in a healthy group of 50-70 yr olds, both acutely and following 28 days of consumption.
Looking for future studies?
Notify Me50 year–70 year
All sexes
Interventional
Not applicable
Newcastle upon Tyne, Tyne and Wear, NE1 8ST, United Kingdom
The presence of polyphenols such as ferulic acid, chlorogenic acid and apigenin in Sideritis Scardica (SS or 'mountain tea') are likely responsible for the cognitive and mood effects of its consumption and this could be underpinned by the ability of such polyphenols to prevent monoamine neurotransmitter reuptake and to increase cerebral blood flow (CBF).
The current randomised, placebo controlled, parallel groups study extends on the abovementioned small amount of literature; assessing both cognitive and mood outcomes in a sample of older (50-70 yrs) adults, as well as blood pressure (BP) and CBF, in a sub-sample, utilizing near-infrared spectroscopy (NIRS). The above will be assessed acutely (pre-dose and 90- and 310-mins post dose) on day 1 and following 28 days consumption of either a placebo control, and active control of 240 mg ginkgo biloba, 475 mg SS or 950 mg SS.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant
Other names: Shepherd's tea, Olympus tea, Mountain tea
Ginkgo biloba is an extract from the ginkgo tree comprising ginkgolides and bilobalide. In this trial Ginkgo acted as an active control.
An inert encapsulated powder provided by Finzelberg.
Time frame: Pre-dose and 90- and 310-mins post-dose on day 1 and on day 28 of consumption
Acute and chronic change in cognitive function via the following cognitive tasks: numeric working memory, choice reaction time, corsi blocks, serial 3 and 7 subtractions, rapid visual information processing, peg and ball, name to face recall, picture recognition, word recognition, immediate word recall and delayed word recall. All tasks provide an outcome for accuracy, speed and error.
Time frame: Pre-dose and between ~150-240-mins post-dose on day 1 and on day 28 of consumption
Blood flow changes measured in the pre-frontal cortex utilizing Near-Infrared Spectroscopy (NIRS). Outcome measures include; oxygen saturation, oxygenated haemoglobin, deoxygenated haemoglobin and total haemoglobin.
Time frame: On day 1 and following 28 days of consumption
Acute and chronic changes in mood as assessed by the State-Trait anxiety Inventory (Spielberger, 1983) and Bond-Lader (1974) visual analogue scales. For both measures a baseline score is calculated and all subsequent post-dose scores are subtracted from this to produce change (change from baseline) scores. Both the STAI and Bond-Lader scales produce numerical values and the outcome measure for both will be the same; i.e. changes in this numerical value from baseline mood.
Time frame: Pre-dose and 90- and 310-mins post-dose on day 1 and on day 28 of consumption
Acute and chronic changes in blood pressure.
Northumbria University
Other
The Acute and Chronic Cognitive and Cerebral Blood Flow Effects of a Sideritis Scardica (Mountain Tea) Extract: a Double Blind, Randomized, Placebo Controlled, Parallel Groups Study in Healthy Humans
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04961086
Blood Glucose, High, Blood Pressure
Karachi, None Selected, Pakistan
View Trial DetailsNCT04015258
Blood Pressure, Cognitive Change
Newcastle upon Tyne, Tyne and Wear, United Kingdom
View Trial DetailsNCT03475836
Affect, Cognitive Change
View Trial DetailsNCT03473678
Blood Pressure, Brain Metabolism
Exeter, Devon, United Kingdom
View Trial Details